当前位置:
X-MOL 学术
›
JACC Heart Fail.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis
JACC: Heart Failure ( IF 10.3 ) Pub Date : 2024-09-25 , DOI: 10.1016/j.jchf.2024.08.003 Andrew J.S. Coats DM DSc, Stefan D. Anker MD PhD, Lars H. Lund MD PhD, Gerasimos Filippatos MD, Patrick Rossignol MD PhD, Bertram Pitt MD, Matthew R. Weir MD, Mikhail N. Kosiborod MD, Marco Metra MD, Michael Böhm MD, Justin A. Ezekowitz MBBCh MSc, Antoni Bayes-Genis MD PhD, Robert J. Mentz MD, Piotr Ponikowski MD PhD, Michele Senni MD PhD, John G.F. Cleland MD PhD, Assen Goudev MD PhD, Irakli Khintibidze MD PhD, Joann Lindenfeld MD, Bela Merkely MD PhD, Sandra Waechter PhD, Jeffrey Budden BSc, Amandine Perrin MSc, Javed Butler MD MPH MBA
JACC: Heart Failure ( IF 10.3 ) Pub Date : 2024-09-25 , DOI: 10.1016/j.jchf.2024.08.003 Andrew J.S. Coats DM DSc, Stefan D. Anker MD PhD, Lars H. Lund MD PhD, Gerasimos Filippatos MD, Patrick Rossignol MD PhD, Bertram Pitt MD, Matthew R. Weir MD, Mikhail N. Kosiborod MD, Marco Metra MD, Michael Böhm MD, Justin A. Ezekowitz MBBCh MSc, Antoni Bayes-Genis MD PhD, Robert J. Mentz MD, Piotr Ponikowski MD PhD, Michele Senni MD PhD, John G.F. Cleland MD PhD, Assen Goudev MD PhD, Irakli Khintibidze MD PhD, Joann Lindenfeld MD, Bela Merkely MD PhD, Sandra Waechter PhD, Jeffrey Budden BSc, Amandine Perrin MSc, Javed Butler MD MPH MBA
For heart failure with reduced ejection fraction (HFrEF), suboptimal use of renin-angiotensin-aldosterone system inhibitors (RAASis), including mineralocorticoid receptor antagonists (MRAs), due to hyperkalemia, may be improved by potassium binders.
中文翻译:
Patiromer 用于当前或过去高钾血症患者心力衰竭药物优化的分析:DIAMOND 亚分析
对于射血分数降低的心力衰竭 (HFrEF),钾结合剂可能会改善由于高钾血症引起的肾素-血管紧张素-醛固酮系统抑制剂 (RAASis) 的次优使用,包括盐皮质激素受体拮抗剂 (MRA)。
更新日期:2024-09-25
中文翻译:
Patiromer 用于当前或过去高钾血症患者心力衰竭药物优化的分析:DIAMOND 亚分析
对于射血分数降低的心力衰竭 (HFrEF),钾结合剂可能会改善由于高钾血症引起的肾素-血管紧张素-醛固酮系统抑制剂 (RAASis) 的次优使用,包括盐皮质激素受体拮抗剂 (MRA)。